Filing Details

---

	SCHEDULE 13D
	UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. __)*

Page 2 of 15

CUSIP No. G07031100                                                                                                                                                                                                                                                                                                    

Page 3 of 15

CUSIP No. G07031100                                                                                                                                                                                                                                                                                                    

(2)

The percentage calculated is based on 619,979,342 Class A Shares outstanding as of November 3, 2022 as reported in the Form 6-K filed by the Issuer on November 4, 2022, which includes (i) 189,924,499 Class A Shares issued in a private placement pursuant to the 2022 PIPE Subscription Agreements (defined below) reported in the Form 6-K filed by the Issuer on November 4, 2022 and (ii) 79,637,576 Class A Shares that were converted into Class A Shares from the total outstanding Class B ordinary shares in accordance with Article 8(a) of the Issuer’s Articles reported in the Form 6-K filed by the Issuer on November 4, 2022.

Page 4 of 15

CUSIP No. G07031100                                                                                                                                                                                                                                                                                                    

Page 5 of 15

CUSIP No. G07031100                                                                                                                                                                                                                                                                                                   

SCHEDULE 13D

Item 1. Security and Issuer

This statement on Schedule 13D (this “Schedule 13D”) relates to the Class A Shares of Babylon Holdings Ltd. (the “Issuer”), whose principal executive offices are located at 1 Knightsbridge Green, London, SW1X 7QA, United Kingdom.

Item 2. Identity and Background

i.	VNV (Cyprus) Limited (“VNV Cyprus”);

ii.	Global Health Equity (“Cyprus) Ltd (Global Health Equity”);

iii.	VNV Sweden AB (“VNV Sweden”); and

iv.	VNV Global AB (publ) (“VNV Global”).

i.	VNV Cyprus: 1, Lampousas Street, 1095 Nicosia, Cyprus;

ii.	Global Health Equity: Stasikratous, 22, Olga Court, Office 104, 1065 Nicosia, Cyprus;

iii.	VNV Sweden: Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden; and

iv.	VNV Global: Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden.

The name, business address, present principal occupation or employment and citizenship of each director and executive officer of the Reporting Persons are set forth on Schedule I hereto and incorporated herein by reference.

In connection with the De-SPAC Transaction, the Issuer, VNV Cyprus and certain other investors entered into a registration rights agreement dated as of June 3, 2021 (the “Registration Rights Agreement”), with respect to certain shares held by the investors, including Class A Shares (the “2021 PIPE Shares”) acquired pursuant to the subscription agreements, dated as of June 3, 2021, entered into, by and among the Issuer, the SPAC and certain subscribers, whereby VNV Cyprus acquired 500,000 2021 PIPE Shares at a price of $10.00 per share. The registration rights pursuant to the Registration Rights Agreement, include certain piggyback registration rights and customary demand registration rights.

Pursuant to the 2022 PIPE Subscription Agreements, the Subscribers are entitled to registration rights for their 2022 PIPE Shares under the Registration Rights Agreement and the Issuer agreed to file a registration statement for a shelf registration covering the 2022 PIPE Shares within 20 days of the Closing Date, to use commercially reasonable efforts to have the registration statement be declared effective as soon as practicable thereafter and to file amendments as necessary.

The foregoing description of the Registration Rights Agreement and any other registration rights under the 2022 PIPE Subscription Agreements, does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement and the 2022 PIPE Subscription Agreements, copies of which are attached as Exhibits 99.2 and 99.3 to this Schedule 13D and are incorporated herein by reference.

General

The Reporting Persons and their respective representatives have engaged and/or may engage, from time to time, in discussions with the Issuer’s management and/or board of directors (the “Board”), including any special committees of the Board, and/or their respective advisors, regarding, among other things, the Issuer’s business, strategies, management, governance, operations, personnel, performance, financial matters, capital structure, corporate expenses, status of projects, hedging, environmental, health and safety matters and strategic and other transactions (including transactions involving one or more of the Reporting Persons and/or their respective affiliates and/or portfolio companies and/or other stockholders or creditors of the Issuer), and have engaged and/or intend to, from time to time, engage in discussions with other current or prospective holders of Class A Shares and/or other equity, debt, notes, instruments or securities, or rights convertible into or exchangeable or exercisable for Class A Shares or such other equity, debt, notes, instruments or securities, of the Issuer (collectively, “Securities”), industry analysts, research analysts, rating agencies, existing or potential strategic partners of the Issuer, acquirers or competitors, financial sponsors, investment firms, investment professionals, capital and potential capital sources (including co-investors), operators, financial, and other consultants and advisors and other third parties regarding such matters (in each case, including with respect to providing or potentially providing capital to the Issuer or to existing or potential strategic partners or acquirers of the Issuer) as well as other matters set forth in clauses (a)-(j) of Item 4 of Schedule 13D. These discussions have encompassed, and/or the Reporting Persons expect will encompass, a broad range of matters relating to the Issuer , including, among other things, the Issuer’s business, operations, finances, management, organizational documents, ownership, capital and corporate structure, dividend policy, corporate governance, the Board and committees thereof, management and director incentive programs, strategic alternatives and transactions, including the sale of the Issuer, its Securities or one or more of its subsidiaries or their respective businesses or assets or a business combination or other strategic transaction involving the Issuer or one or more of its subsidiaries, and any regulatory or legal filings, clearances, approvals or waivers relating to the foregoing. The Reporting Persons may exchange information with the Issuer or other persons or entities pursuant to confidentiality or similar agreements and may enter into expense reimbursement agreements with the Issuer and others.

The Reporting Persons intend to review their investment in the Issuer on an ongoing basis. Depending on various factors, including the outcome of any discussions referenced above, the Issuer’s business, financial position, results, strategic direction or prospects or any strategic alternatives or transactions, actions taken by the Issuer’s management or the Board, price levels of one or more Securities, other investment opportunities available to the Reporting Persons, the available capital of the Reporting Persons, the respective portfolio management considerations (including investment horizons) of the Reporting Persons, conditions in the securities, loan or bond markets, factors relating to COVID-19 and other potential pandemics, general economic or industry conditions or any changes in law or regulations, the Reporting Persons expect that they will seek to dispose, or cause to be disposed (including, without limitation, distributing some or all of the shares of Class A Shares to certain of the Reporting Persons’ respective members, partners, stockholders and/or beneficiaries, as applicable), some or all of the shares of Class A Shares beneficially owned by them, in the public market, in privately negotiated transactions or otherwise, pledging their interest in their shares of Class A Shares as a means of obtaining liquidity or as credit support for loans or other extensions of credit, or entering into derivatives transactions and other agreements or instruments that decrease the Reporting Persons’ economic exposure with respect to their investment in the Issuer.

Certain plans or proposals may from time to time be discussed or considered by the directors of the Issuer, including Per Brilioth, who is both a member of the board of directors of the Issuer and a managing director of VNV Global.

Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

The information set forth or incorporated by reference in Items 2 and 4 of this Schedule 13D is incorporated by reference in this Item 5.

(a)—(b) Based on 619,979,342 Class A Shares outstanding as of November 3, 2022 as reported in the Form 6-K filed by the Issuer on November 4, 2022, which includes (i) 189,924,499 Class A Shares issued in a private placement pursuant to the 2022 PIPE Subscription Agreements (defined below) reported in the Form 6-K filed by the Issuer on November 4, 2022 and (ii) 79,637,576 Class A Shares that were converted into Class A Shares from the total outstanding Class B ordinary shares in accordance with Article 8(a) of the Issuer’s Articles reported in the Form 6-K filed by the Issuer on November 4, 2022.

Except as set forth above, neither the Reporting Persons nor, to the knowledge of the Reporting Persons, any of the persons named in Schedule I hereto, beneficially own any Class A Shares.

(d)—(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information in Item 4 is incorporated herein by reference. Other than the agreements described in Item 4, as of the date hereof, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer.

Item 7. Material to be Filed as Exhibits.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

Date: November 10, 2022

VNV (CYPRUS) LIMITED

Name:  Boris Sinegubko

Title:    Managing Director

GLOBAL HEALTH EQUITY (CYPRUS) LTD

By: P.C. Nordic Administration Limited

Name:  Maria Zembyla, on behalf of P.C. Nordic Administration Limited

Title:     Director

VNV SWEDEN AB

By:        /s/ Per Brilioth               

Name:  Per Brilioth

Title:     Managing Director

VNV GLOBAL AB (PUBL)

By:      /s/ Per Brilioth                

Name:  Per Brilioth

Title:     Managing Director

SCHEDULE I

Directors and Executive Officers of the Reporting Persons

The following table sets forth certain information with respect to the directors and executive officers of the Reporting Persons. The business address of each director and executive officer of VNV (Cyprus) Limited is c/o 1, Lampousas Street, 1095 Nicosia, Cyprus. The business address of each director and executive officer of Global Health Equity (Cyprus) Ltd is c/o Stasikratous, 22, Olga Court, Office 104, 1065 Nicosia, Cyprus. The business address of each director and executive officer of VNV Sweden AB is c/o Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden. The business address of each director and executive officer of VNV Global AB (publ) is c/o Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden.

VNV (CYPRUS) LIMITED

GLOBAL HEALTH EQUITY (CYPRUS) LTD

VNV SWEDEN AB

VNV GLOBAL AB (PUBL)

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the Class A Shares of Babylon Holdings Limited.  The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate. This joint filing agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.

VNV (CYPRUS) LIMITED

Name:  Boris Sinegubko

Title:     Managing Director

GLOBAL HEALTH EQUITY (CYPRUS) LTD

By: P.C. Nordic Administration Limited

Name:   Maria Zembyla, on behalf of P.C. Nordic Administration Limited

Title:     Director

VNV SWEDEN AB

By:      /s/ Per Brilioth                                                                

Name:   Per Brilioth

Title:      Managing Director

VNV GLOBAL AB (PUBL)

By:       /s/ Per Brilioth                                                                       

Name:   Per Brilioth

Title:      Managing Director

---